Streetbeat News

Stock Prices

ARVN

Arvinas (NASDAQ:ARVN) reported Q4 earnings with a significant miss, posting an EPS of $-2.53 against an estimate of $-1.28, marking a -98.0% deviation. Revenue also saw a substantial decrease, down $81.10 million from the previous year. This follows a pattern of fluctuating performance in past quarters, with the last quarter showing a beat on EPS estimates but a subsequent 7% drop in share price.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 1:50 pm

VERV

Verve Therapeutics (NASDAQ:VERV) reported Q4 earnings, beating estimates with an EPS of $-0.69 against an expected $-0.82 and saw a revenue increase of $4.13 million year-over-year. Despite beating last quarter's EPS estimate, the share price dropped by 10% the following day.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 1:50 pm

ALLE

HTLD

ILMN

TTSH

Insiders at Allegion, Heartland Express, Tile Shop Holdings, and Illumina have made significant stock purchases, signaling confidence in their companies' prospects. Allegion's CEO bought shares worth $1.32 million, Heartland Express' 10% owner purchased shares for $185,024, Tile Shop Holdings' 10% owner acquired shares costing around $639,991, and Illumina's CEO bought shares valued at approximately $991,672. These purchases follow positive earnings reports or announcements from the companies.

Portfolio Pulse from Avi Kapoor

February 27, 2024 | 1:47 pm

LOW

Lowe's Companies Inc (NYSE:LOW) reported Q4 FY23 sales of $18.60 billion, slightly above estimates but saw a 6.2% Y/Y decrease in comparable sales due to weak DIY demand and unfavorable weather. Despite this, EPS of $1.77 beat estimates. Gross profit and operating income fell, but margins improved. The company issued a weak FY24 outlook with expected revenue and EPS below consensus estimates, leading to a 1.22% premarket drop in LOW shares.

Portfolio Pulse from Lekha Gupta

February 27, 2024 | 1:46 pm

MCK

McKesson's (NYSE:MCK) short interest has decreased by 5.51%, now representing 1.2% of its float with 1.57 million shares sold short. It would take approximately 2.37 days to cover these short positions. This decline in short interest could indicate a more bullish sentiment towards MCK among traders. Additionally, compared to its peers, McKesson has a lower short interest percentage of 1.2% against an average of 5.04%, suggesting it is performing well relative to its industry counterparts.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 1:45 pm

EW

Edwards Lifesciences (NYSE:EW) has seen a decrease in short interest, with the short percent of float falling 8.29% to 1.66% of all shares available for trading. This indicates a reduction in bearish sentiment among traders. The company's short interest is also lower than its peer group average of 3.89%, suggesting a relatively more positive outlook compared to its peers.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 1:45 pm

PLD

Prologis (NYSE:PLD) has seen a decrease in short interest, with the current short percent of float at 1.16%, down 12.78% from the last report. The company has 9.58 million shares sold short, requiring approximately 2.89 days for traders to cover. This decline in short interest could indicate a more bullish sentiment towards PLD among investors. Additionally, Prologis has a lower short interest compared to its peer group average of 3.84%.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 1:45 pm

HIMS

JANX

PUBM

Shares of Janux Therapeutics (JANX), PubMatic (PUBM), and Hims & Hers Health (HIMS) surged following positive updates. JANX soared 156% after announcing promising clinical data. PUBM jumped 38% on strong Q4 results and future guidance. HIMS increased 22% also due to favorable Q4 outcomes and guidance.

Portfolio Pulse from ryanfaloona@benzinga.com

February 27, 2024 | 1:44 pm

WVE

Wave Life Sciences Ltd. announced its participation in the 2024 MDA Clinical & Scientific Conference, highlighting the potential of WVE-N531 for Duchenne muscular dystrophy (DMD). The presentations will showcase clinical and preclinical data, including the first evidence of satellite cell uptake in DMD therapy, significant drug concentrations in non-human primates, and the impact of Wave's PN chemistry on exon skipping and dystrophin restoration. The FORWARD-53 study is evaluating WVE-N531's ability to restore dystrophin, with 24-week data expected in Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:44 pm

RBA

Ritchie Bros. Auctioneers (NYSE:RBA) reported a successful premier global auction event in Orlando, FL, from Feb. 19-23, generating over $258 million in gross transaction value from the sale of 16,500+ equipment items, trucks, and vehicles. The event attracted 22,000+ bidders from over 80 countries, with 83% of equipment sold to U.S. buyers. Additionally, Ritchie Bros.' online platforms hosted auctions in Australia and on IronPlanet, contributing to a total of over $300 million in GTV sold last week.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:42 pm